Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry

Agency reviewers believed the line between patient input and external intimidation had been crossed; early data from the Sarepta muscular dystrophy drug's flawed development program stoked patient community expectations and made regulatory review difficult.